Mavorixafor is a small molecule commercialized by Abbisko Therapeutics, with a leading Phase III program in WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis). According to Globaldata, it is involved in 13 clinical trials, of which 7 were completed, 2 are ongoing, 2 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Mavorixafor’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Mavorixafor is expected to reach an annual total of $43 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Mavorixafor Overview

Mavorixafor (X4P-001) is under development for the treatment of severe congenital neutropenia, Waldenstrom’s Macroglobulinemia, WHIM syndrome, melanoma and refractory solid tumors including clear cell renal cell carcinoma (ccRCC) and triple-negative breast cancer. It is administered through oral route. The drug candidate was under development for the treatment of human immunodeficiency virus (HIV) Infections (AIDS). The drug candidate acts by targeting C-X-C receptor type 4 (CXCR4).

Abbisko Therapeutics Overview

Abbisko Therapeutics (Abbisko) is a biopharmaceutical company. It discovers and develops of novel medicines to the treatment of cancers and other diseases. Its pipeline immuno-oncology small molecule modulators include ABSK011, ABSK021, ABSK003, ABSK004, and ABSK005 reactivating tumor-specific immune response and human immune system to fight against cancer cells; ABSK006 for the treatment of diabetes. It owns an integrated research and development center in Shanghai Zhangjiang Hi-Tech Park to conduct immune-oncology drug development activities. The company is funded by healthcare investors such as Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital, and TF Capital. Abbisko is headquartered in Shanghai, China.

The company reported revenues of (Renminbi) CNY22.7 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was CNY1,809 million in FY2021, compared to an operating loss of CNY706.3 million in FY2020. The net loss of the company was CNY1,810 million in FY2021, compared to a net loss of CNY706.6 million in FY2020.

For a complete picture of Mavorixafor’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.